CCS Gap Assessment Checklist for Pharma Sterile Sites

Last reviewed 12 Nov 2026 · 6 min read

Contents
  1. Purpose of a CCS gap assessment
  2. How to use the checklist
  3. Gap-assessment worksheet
  4. Worked fictional example
  5. Common mistakes
  6. Frequently asked questions
  7. Is a CCS the same as an environmental monitoring programme?
  8. Does EU GMP Annex 1 prescribe this checklist or a fixed score?
  9. Can the sterile-product guidance be used for a non-sterile product?
  10. What records should support closure of a gap?
  11. References
  12. Related reading

In short: A contamination control strategy (CCS) connects the controls that protect a medicinal product from microbial, particulate and endotoxin or pyrogen contamination. This checklist helps a sterile-site team find missing links between risks, controls, monitoring, investigations and management review. Use it as a gap-assessment aid; the site’s approved procedures, risk assessments and applicable requirements remain the working basis.

Purpose of a CCS gap assessment

EU GMP Annex 1 describes a CCS as a facility-wide strategy that identifies critical control points and assesses the effectiveness of design, procedural, technical and organisational controls together with monitoring. It also calls for active review and appropriate updates. The Annex is guidance for sterile-product manufacture. It notes that some principles may also support certain non-sterile products where contamination control matters, provided the manufacturer documents which principles it applies and demonstrates compliance.

A checklist can make the assessment easier to follow, but a completed row is not proof that a control works. The assessment should connect each meaningful contamination risk to a control, supporting evidence, a monitoring or review mechanism, and a response when performance is not as expected. Consider the entire facility and product lifecycle rather than treating environmental monitoring as the whole CCS.

Requirements depend on the markets served, product type and the site’s commitments. Check the applicable local GMP, marketing authorisation and registered process before using a reference as a site requirement. For context, see production of sterile pharmaceutical products and the cleanroom facility guidance.

How to use the checklist

  1. Set the scope. Identify the site, buildings, products, operations and interfaces included. Record whether the assessment covers sterile manufacture, a non-sterile process using selected CCS principles, or both.
  2. Gather current evidence. Ask control owners for approved procedures, qualification and validation records, monitoring trends, investigations, change assessments and supplier or outsourced-service controls. Use controlled records rather than informal descriptions.
  3. Map risk to control. For each topic, record the contamination source or failure mode, the control that addresses it, and evidence that supports the control’s design and continued performance.
  4. Assess links and interfaces. Look for gaps where several controls rely on one another, such as component sterilisation, transfer into a cleanroom, aseptic connections, environmental monitoring and intervention handling.
  5. Record findings and actions. Document the gap, product or process impact, rationale for risk ranking, action owner, target date and objective closure evidence. A local scoring scale is a site choice; explain it in the controlled procedure.
  6. Review and maintain. Route findings through the site quality system. Revisit the CCS after relevant changes, significant problems or new information, and include its effectiveness in periodic management review as applicable.

Gap-assessment worksheet

The topics below reflect examples listed in EU GMP Annex 1 (2022), §2.5. The list is explicitly non-exhaustive. Add topics needed for the site’s products and processes. The worksheet is a working aid, not a substitute for a facility-specific risk assessment.

TopicRisk or failure modeCurrent control and evidence referenceEffectiveness / gap findingRisk rationaleAction, owner and due dateClosure evidence
Plant and process design
Premises and equipment
Personnel and interventions
Utilities
Raw materials and in-process controls
Product containers and closures
Suppliers and outsourced activities
Process and sterilisation validation
Preventive maintenance
Cleaning and disinfection
Monitoring and trend review
Investigation, root cause and CAPA
Change management and continual improvement

Record the document identifier and version for each evidence item so another reviewer can retrieve it. If one control addresses more than one topic, cross-reference it and explain the interaction instead of assuming that the overlap is understood. EU GMP Annex 1, §2.5 lists plant and process design, premises, equipment, personnel, utilities, materials, containers and closures, suppliers, outsourced activities, process risk management, process validation, sterilisation validation, maintenance, cleaning, monitoring, investigation and continual improvement among the elements to consider.

Worked fictional example

Fictional example — transfer of sterile components: A team notices that its component transfer procedure describes the validated sterilisation cycle but does not clearly connect post-cycle status identification with the transfer route into the aseptic area. The team records the risk as a possible mix-up or contamination during transfer, links the applicable procedure and qualification records, and checks the current transfer practice with the control owner. The finding is assigned a risk rationale using the site’s approved method. An action updates the controlled transfer instructions and training, then checks effectiveness using an approved verification activity. The CCS records the linked controls and the evidence used to close the finding.

This example does not establish a universal transfer method, risk score, sample size or acceptance limit. Those decisions depend on the qualified process and the site’s risk assessment.

Common mistakes

  • Treating monitoring as the strategy. Annex 1 places monitoring alongside facility, equipment, process and procedural design. Trend data can reveal weak controls, but monitoring alone does not create contamination prevention.
  • Copying a generic topic list without assessing the site. Annex 1 calls its list of CCS elements non-exhaustive. Explain why each relevant risk is controlled and identify additional product-specific or facility-specific risks.
  • Listing procedures without testing the connection. A procedure can exist while its interface with another operation remains unclear. Link the controls and assess their combined effectiveness.
  • Closing actions on document revision alone. State what evidence will show that the action was implemented and effective; use the site’s approved change and CAPA processes.
  • Using an unexplained rating scale. Risk categories, scores, review triggers and target dates are site choices. Document them as an example in-house criterion only when showing an illustrative local approach, and do not present them as Annex 1 limits.
  • Forgetting product and market scope. A sterile facility may serve more than one market. Identify which requirements and commitments apply before deciding that a gap is closed.

Frequently asked questions

Is a CCS the same as an environmental monitoring programme?

No. Environmental and process monitoring is one element to consider. A CCS also connects facility and process design, equipment, personnel, materials, cleaning, maintenance, validation, supplier controls, investigations and other relevant measures.

Does EU GMP Annex 1 prescribe this checklist or a fixed score?

No. This worksheet is an educational aid. Annex 1 §2.5 identifies topics to consider and says the list is not exhaustive; it does not prescribe this worksheet, a universal score or a single way to assess gaps.

Can the sterile-product guidance be used for a non-sterile product?

Annex 1 says some principles, including CCS, may support certain non-sterile products where contamination control is important. It also says the manufacturer should document which principles it applies and demonstrate compliance. Confirm the applicable requirements for the product and market.

What records should support closure of a gap?

Use the controlled evidence that demonstrates the agreed action was completed and the control is effective. For batch-specific production or control records, EU GMP Volume 4, Chapter 4 §4.11 requires batch documentation to be kept for one year after batch expiry or at least five years after Qualified Person certification, whichever is longer; 21 CFR 211.180(a) requires at least 1 year after the batch expiration date. Apply any longer or product-specific period that governs the record.

References

  • European Commission, EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products, 2022, especially §§2.1–2.6. The European Commission lists the Annex as fully applicable since 25 August 2024: official Annex 1 PDF and EudraLex Volume 4 status page.
  • European Commission, EudraLex Volume 4, Chapter 4: Documentation, revision 1, effective 30 June 2011, §§4.11–4.12: official PDF.
  • 21 CFR Part 211, current eCFR through 6 November 2026, §211.180(a): eCFR.

Related articles